EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of an Enzyme Immunoassay versus Mass Spectrometry-based Assay for the Quantitative Determination of the Procollagen Type I N-terminal Propeptide in Rat Serum

Monika Dzieciatkowska, Marci Copeland, Jinsam You, Jean-Pierre Wery, Mu Wang

Proteomics Insights · 2009

DOI: 10.4137/pri.s3454 ↗
AbstractBibliografische Angaben

Abstract

Traditionally, antibody-based assays, such as enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA), are the primary tool for the targeted quantification of a specific protein. An antibody-based assay can be run at high-throughput and has extraordinary sensitivity and specificity. In the cases where antibody-based assays exist, the process of validating biomarker candidates can be relatively straightforward. However, the antibody-based approach is limited by the lack of availability of antibodies with high specificity. The development of a high quality antibody-based assays can be costly, time-consuming and a resource-intensive effort. Another disadvantage of antibody-based assays is that they often do not discriminate closely related isoforms. While the antibody development is central to the success of antibody-based platform, mass spectrometry (MS) provides alternative and complementary approach to existing antibody-based assays. The MS-based assays are becoming very popular for quantitative candidates proteins detection in a complex biological mixture. In the present paper, an in-house developed mass spectrometry (MS)-based assay was compared to a commercially available EIA in reproducibility, measurement accuracy, and dynamic range using rat procollagen type-I N-terminal propeptide (P1NP) as a model.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →